Last edition
News about "Facioscapulohumeral Muscular Dystrophy "
Del-Brax from Novartis Achieves Primary Biomarker Endpoint in FSHD Study
Novartis reported positive phase 1/2 FORTITUDE study results for delpacibart braxlosiran (del-brax) in FSHD, meeting primary and key secondary biomarker endpoints. The therapy could become the first disease-modifying treatment for FSHD, with a phase 3 trial underway.
Facioscapulohumeral Muscular Dystrophy | 12/06/2026 | By News Bureau
Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD
Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.
Facioscapulohumeral Muscular Dystrophy | 25/03/2026 | By News Bureau | 262
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy